Neurology

TeleSpecialists Revolutionizes Stroke Care with Launch of Innovative EMS Integration Service

EMS Integration to enhance door-to-needle times and elevate patient outcomes FORT MYERS, Fla., July 16, 2024 /PRNewswire/ -- TeleSpecialists, LLC,…

5 months ago

Calidi Biotherapeutics Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Former NIH/National Cancer Institute neuro-oncology leader adds in-depth government healthcare agency expertise to CalidiSAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE)…

5 months ago

Cumulus Neuroscience to Join Bio-Hermes 2 Study with Funding from the Innovate UK Small Business Research Initiative (SBRI) Dementia Mission Project

Funded by a nearly £1.2M (~$1.5M USD) award, this research will enable ongoing validation of AccelADx™, a breakthrough screening test for…

5 months ago

Bausch Health to Announce Second Quarter 2024 Results on August 1, 2024

LAVAL, QC / ACCESSWIRE / July 11, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2024 financial…

5 months ago

Skyhawk Therapeutics Announces Positive Topline Results from Parts A and B of its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease, Reaching 72% Huntingtin mRNA Reduction

Skyhawk’s SKY-0515 demonstrated dose-dependent huntingtin (HTT) mRNA reduction in healthy volunteers, with 72% reduction at the highest dose tested in…

5 months ago

Evotec and Pfizer Collaborate to Advance Drug Discovery in France

Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG, GERMANY / ACCESSWIRE / July…

5 months ago

Nxera Pharma Webinar Presentation for Q2 FY2024 Financial Results

Tokyo, Japan and Cambridge, UK, 9 July 2024 - Nxera Pharma Co. Ltd (“Nxera”; TSE 4565) will announce its earnings…

5 months ago

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of…

5 months ago

Paragon Genomics Partners with Biosecure ID to Expand Access to CleanPlex® Technology in the UK and Ireland

--Follows A Half Dozen New Distributor Agreements Around the Globe for Paragon Genomics’ Unique CleanPlex® NGS Target Enrichment Technology--FREMONT, Calif.,…

5 months ago